BAMCO Inc’s Xenon Pharmaceuticals XENE Stock Holding History

BAMCO Inc’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51M	Hold	25,000	–	–	﹤0.01%	291
2026 Q1	$1.45M	Sell	25,000 -5,000	-17%	-$230K	﹤0.01%	287
2025 Q4	$1.34M	Hold	30,000	–	–	﹤0.01%	294
2025 Q3	$1.2M	Sell	30,000 -26,000	-46%	-$916K	﹤0.01%	296
2025 Q2	$1.75M	Sell	56,000 -44,100	-44%	-$1.44M	﹤0.01%	277
2025 Q1	$3.36M	Hold	100,100	–	–	0.01%	269
2024 Q4	$3.92M	Hold	100,100	–	–	0.01%	260
2024 Q3	$3.94M	Hold	100,100	–	–	0.01%	275
2024 Q2	$3.9M	Hold	100,100	–	–	0.01%	270
2024 Q1	$4.31M	Hold	100,100	–	–	0.01%	276
2023 Q4	$4.61M	Hold	100,100	–	–	0.01%	269
2023 Q3	$3.42M	Hold	100,100	–	–	0.01%	274
2023 Q2	$3.85M	Buy	100,100 +27,100	+37%	+$1.08M	0.01%	275
2023 Q1	$2.61M	Buy	73,000 +25,600	+54%	+$946K	0.01%	286
2022 Q4	$1.87M	Buy	47,400 +19,900	+72%	+$725K	0.01%	314
2022 Q3	$993K	Buy	27,500 +5,500	+25%	+$198K	﹤0.01%	330
2022 Q2	$669K	Sell	22,000 -20,000	-48%	-$605K	﹤0.01%	344
2022 Q1	$1.28M	Hold	42,000	–	–	﹤0.01%	348
2021 Q4	$1.31M	Buy	+42,000	New	+$1.26M	﹤0.01%	362

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BAMCO Inc's XENE Position: Q2 2026 in Review

BAMCO Inc held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 25,000 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #291.

BAMCO Inc first reported a position in XENE in Q4 2021 and has held it in 19 quarters since. The position peaked at $4.61M in Q4 2023. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

BAMCO Inc held 25,000 shares of Xenon Pharmaceuticals worth $1.51M as of Q2 2026.
BAMCO Inc left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of BAMCO Inc's portfolio in Q2 2026, its #291 holding.
BAMCO Inc first reported a position in Xenon Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
BAMCO Inc's Xenon Pharmaceuticals position peaked at $4.61M in Q4 2023.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on BAMCO Inc's 13F filing for Q2 2026, filed 14 Aug 2026.